QuidelOrtho (QDEL)

NASDAQHealth CareMedical - SpecialtiesSnapshot 2026-10-23

$13.73+1.85%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge QuidelOrtho’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-28
Revenue	—	665.36M
EPS	—	0.47
Annual ending 2026-12-28
Revenue	—	2.54B
EPS	—	0.771
Annual ending 2027-12-28
Revenue	—	2.59B
EPS	—

What the Thesis Depends On

5 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Adjusted EBITDA margin near 17.5% in FY26	A primary condition in QuidelOrtho's published investment case. The stated target is >= 17.5%.	Improving	Margin falls below 17.5% in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Adjusted EBITDA margin declined from 22% in 2025-Q4 to 17.5% in 2026-Q1 but improved to 20.5% in 2026-Q2. Free cash flow guidance was withdrawn in 2026-Q2 after prior positive guidance. Management continues to emphasize margin expansion and cash flow improvement, showing mixed delivery with recent margin recovery but cash flow challenges.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-28 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	1 / 3
2026-07-25	Unavailable	Unavailable	1 / 3
2026-07-26	Unavailable	Unavailable	1 / 3
2026-07-27	Unavailable	Unavailable	1 / 3
2026-07-28	Unavailable	Unavailable	1 / 3
2026-07-29	Unavailable	Unavailable

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Adjusted EBITDA margin near 17.5% in FY26Direct metric needs a verified mapping
Manage China NHSA pricing and geopolitical disruptionsDirect metric needs a verified mapping
Free cash flow at least $100 million in FY26Published status: Broken
Revenue at or above $2.7 billion in FY26Published status: Broken

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.7%Typical daily move · historical

Downside history

-71.9%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

QuidelOrtho outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a higher-risk healthcare business with a multi-year view tied to product growth, acquisitions, and better margins. The thesis is currently intact, though recent earnings have been erratic and management’s cash-flow delivery is mixed.

What's priced into QuidelOrtho

The evidence describes QDEL as cheap versus peers, with a negative expectations gap, while its pricing is tagged as justified and fragility is low. That suggests modest expectations, but confidence in the valuation read is only medium and the company is loss-making.

What the fundamentals likely do

Near term, the latest margin recovery offers some support, but withdrawn free-cash-flow guidance and a recent quarterly miss leave execution uncertain. Over the multi-year view, Point of Care growth and the LEX Diagnostics acquisition support expansion, while China revenue pressure and weaker employment data are risks.

What QuidelOrtho hinges on

A key near-term swing factor is whether QDEL reverses its lowered guidance and improves execution at the next update. The broader setup also depends on China-related pressure easing, margins and cash flow improving, and healthcare peers continuing to report strength.

Bottom line

Over the next one to three years, the long-term thesis rests on turning product growth into durable margins and cash flow, with elevated execution and economic risks. Not investment advice.

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.

What could strengthen or challenge QuidelOrtho’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-28
Revenue	—	665.36M
EPS	—	0.47
Annual ending 2026-12-28
Revenue	—	2.54B
EPS	—	0.771
Annual ending 2027-12-28
Revenue	—	2.59B
EPS	—

Measure / period

Management expectations

Analyst expectations

Quarter ending 2026-12-28

Revenue

—

665.36M

EPS

—

0.47

Annual ending 2026-12-28

Revenue

—

2.54B

EPS

—

0.771

Annual ending 2027-12-28

Revenue

—

2.59B

EPS

—

Key Factor

Why It Matters

Current Status

Break Condition

Latest Evidence

Adjusted EBITDA margin near 17.5% in FY26

A primary condition in QuidelOrtho's published investment case. The stated target is >= 17.5%.

Improving

Margin falls below 17.5% in FY26

Direct metric needs a verified mapping

The published measure or accounting basis is not supported by an exact source binding.

Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes

Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Management context

Stated as a priority in 3 of last 3 quarters. Adjusted EBITDA margin declined from 22% in 2025-Q4 to 17.5% in 2026-Q1 but improved to 20.5% in 2026-Q2. Free cash flow guidance was withdrawn in 2026-Q2 after prior positive guidance. Management continues to emphasize margin expansion and cash flow improvement, showing mixed delivery with recent margin recovery but cash flow challenges.

FY2027 estimate observations · fmp

Snapshot

EPS

Revenue

EPS / revenue analysts

2026-07-24

Unavailable

1 / 3

2026-07-25

Unavailable

1 / 3

2026-07-26

Unavailable

1 / 3

2026-07-27

Unavailable

1 / 3

2026-07-28

Unavailable

1 / 3

2026-07-29

Unavailable

Date	Buy*	Hold	Sell*
2026-05-01	2	4	1
2026-06-01	1	3	1
2026-07-01	1	3	1
2026-08-01	1	1	1
2026-09-01	1	1	1
2026-10-01	1	1	1

QuidelOrtho (QDEL)

What could strengthen or challenge QuidelOrtho’s outlook?

What the Thesis Depends On

Incoming Evidence

Expectations trend

Outlook in Brief

What's improving

Still unresolved / key risks

Historical risk context

QuidelOrtho outlook in detail

What kind of bet this is

What's priced into QuidelOrtho

What the fundamentals likely do

What QuidelOrtho hinges on

Bottom line

What could strengthen or challenge QuidelOrtho’s outlook?

What the Thesis Depends On

Incoming Evidence

Expectations trend

Outlook in Brief

What's improving

Still unresolved / key risks

Historical risk context

QuidelOrtho outlook in detail

What kind of bet this is

What's priced into QuidelOrtho

What the fundamentals likely do

What QuidelOrtho hinges on

Bottom line

Analyst view

Price-target changes

Next proof point

Bottom line